In adulthood, steroid 5-reductases (Srd5) are known to synthesize androgens from testosterone and to play important physiological roles, in particular during reproduction. However, less is known about their regulation and function during early development. To deepen the understanding on Srd5 in amphibian species, we investigated the mechanistic regulation of four important genes (srd5α1, srd5α2, srd5α3, and srd5β) via 1) chemical enzymatic inhibition and 2) specific DNA methylation imprinting. Indeed, this is the first study to suggest that Srd5 are functional during the critical early developmental period of vertebrates. Moreover, exposure to Srd5 inhibitors showed that the regulation of srd5 in early development are self-regulated, with decreasing mRNA levels after exposure, consistent to the regulation mechanism in juvenile frog liver. Furthermore, data highlighted a potential novel mechanism of regulation for srd5α1 and srd5α3, i.e., through DNA methylation. This opens up important questions regarding the role of a transgenerational effect in the regulation of these crucial genes through maternal transfer. This study also profiled the expression of srd5 throughout early development for the first time in any vertebrate and suggested that steroid metabolites produced by Srd5 have crucial roles in development of the central nervous, sensory, cardiac, respiratory, and detoxifying systems aside from reproduction in early anuran development.
Introduction
One of the most important functions of steroid 5-reductases (Srd5) in adult vertebrates is androgen biosynthesis. Specifically, Srd5α or Srd5β convert the main circulating androgen testosterone (T) into the more potent androgen 5α-dihydrotestosterone (5α-DHT) or 5β-dihydrotestosterone (5β-DHT), respectively. Precisely, there are a total of three Srd5α isoforms (i.e., Srd5α1, Srd5α2, and Srd5α3) responsible of converting delta 4,3-keto steroids into their respective 5α-metabolites. In mammals, Srd5α1 is mainly present in non-androgen tissues, including skin; Srd5α2 is predominantly found in reproductive tissues such as testes, while Srd5α3 is ubiquitously distributed throughout the body (reviewed in Langlois et al., 2010a) . In contrast, Srd5β is mostly associated to the liver in mammals due to its crucial role in bile biosynthesis (Chen and Penning, 2014) . In adult frogs, srd5β transcripts have also been found in adult brain and gonads, suggesting other functions than bile biosynthesis (Bissegger and Langlois, 2016) . Previous research also demonstrated that Srd5β is involved in neurosteroid synthesis, initiation of steroid hormone clearance, erythropoiesis, and vasorelaxation (reviewed in Langlois et al., 2010a; Chen and Penning, 2014) . While the involvement of Srd5 in crucial biological functions is known in adulthood, the presence of Srd5 and its associated gene regulation during embryogenesis and early development remains unclear.
Expression of srd5 has been shown to be activated by hormones (Chang, 2002) , but studies have also suggested that DNA methylation regulates these genes throughout development (Ehrlich, 2003) , leading to the assumption that this epigenetic mechanism could also be involved in regulating srd5 throughout early development. As a part of epigenetics, DNA methylation is crucial for tissue-specific gene expression (Chen and Riggs, 2005) . The addition of methyl groups to the cytosine in a cytosine guanidine dinucleotide (CpG) is often associated with gene silencing, by either blocking the access of transcription factors to the promoter site or forming a tight chromatin structure that creates an inactive region (Casati et al., 2015) . Regarding to the influence on srd5 expression regulation, a high DNA methylation level of srd5α2 in human liver corresponds to a low mRNA level of the enzyme (Moribe et al., 2008 ). Moreover, the transcript level of srd5α2 in human lymphocytes is also linked to its DNA methylation state (Rodrıǵuez-Dorantes et al., 2002) . In amphibians, recent research has suggested that the three srd5α isoforms have distinctive DNA methylation patterns in the adult gonads (Bissegger and Langlois, 2016) . Taken together, this suggests that Srd5 could also be regulated by DNA methylation in early development. Mechanisms of Development 141 (2016) [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Accordingly, the primary objective was to investigate the regulation of srd5 during early frog development, and for this, enzyme inhibition and specific DNA methylation imprinting for srd5α were assessed as potential mechanisms of regulation of srd5 mRNA levels. The secondary objective of this study was to localize all four srd5 using whole mount in situ hybridization during this critical developmental period in order to help elucidate the early roles of Srd5 in localizing their transcriptional activity in the various organ systems.
Materials and methods

Animals
Male and female Silurana tropicalis were kept in dechlorinated and aerated water at the Queen's University Animal Care facilities (Kingston, ON, Canada) in accordance with the Institution's animal care protocols and the Canadian Council on Animal Care guidelines. Animals were kept in a 12:12 h light:dark cycle with a water temperature of 26 ± 1°C. Fertilized eggs were obtained by injection of 12.5 IU human chorionic gonadotropin (hCG, Fisher Scientific, Toronto, ON, Canada) into the dorsal lymph sac of both male and female S. tropicalis followed by a boosting injection of 100 IU hCG after 24 h. The fertilized eggs were dejellied using 2% (w/v) L-cysteine 
Enzymatic inhibition
Once 600 eggs reached NF 13 (embryonic stage undergoing neurulation), the embryos were exposed to either 1% ethanol, 100 μM finasteride (FIN) delivered in 1% ethanol, 100 μM chenodeoxycholic acid (CA) delivered in 1% ethanol, 100 μM ursodeoxycholic acid (UA) delivered in 1% ethanol, or no additive (water control to ensure 1% ethanol did not affect the animals). Originally, FIN was developed as a human drug to specifically target SRD5α2 (reviewed in Chen and Penning, 2014) , but FIN was also shown to successfully inhibit srd5α2 and srd5β mRNA levels in frogs (Langlois et al., 2010b) . CA and UA were chosen as specific inhibitors for Srd5β. CA and UA are bile acids that have been previously shown to inhibit human SRD5β via a non-competitive mechanism (Chen et al., 2011) . Little is known about their exact mechanism of action, but it is suggested that CA and UA provide feedback inhibition if bile acid concentration exceeds a specific level in liver (Chen et al., 2011) . The concentration of FIN was chosen according to a previous study that showed successful Srd5 inhibition in frogs (Langlois et al., 2010b) . Due to a lack of literature suggesting CA and UA inhibition in frogs, the same concentration of CA, UA, and FIN was chosen. At stage NF 34, 100 embryos of each treatment were washed in distilled water and fixed in MEMFA solution (pH 7.4, 0.1 M MOPS, 2 mM EGTA, 1 mM MgSO4, and 3.7% formaldehyde) for 1 h. The MEMFA solution was then exchanged with absolute ethanol and the embryos were stored at −20°C before further analysis by in situ hybridization.
Developmental profile and embryo preparation
Approximately 100 embryos for DNA isolation and subsequent DNA methylation analysis were collected at NF stages 2, 13, 21, 25, 31, 34, 41, and 46 and flash frozen on dry ice in pools (20 embryos for NF 2 to NF 34, 15 embryos for NF 41, and 10 embryos for NF 46). The samples were stored at −80°C before further analysis.
In addition, 100 embryos were collected at NF stages 7, 13, 17, 21, 25, 31, 34, 41, and 46 to establish the localization profile of srd5α1, srd5α2, srd5α3, and srd5β transcripts performed by in situ hybridization. Once reached the targeted developmental stages, the embryos were washed in distilled water and fixed in MEMFA. The MEMFA solution was then exchanged with absolute ethanol and the embryos were stored at −20°C before further analysis.
DNA methylation analysis
DNA from frog embryos was isolated using the Qiagen Blood and Tissue kit (Qiagen, Toronto, ON, Canada) . Concentration and quality were assessed by NanoDrop 2000 (Nanodrop Technologies, Wilmington, DE, USA). Primers to assess the specific DNA methylation in the promoter region of srd5α1, srd5α2, and srd5α3 in S. tropicalis embryo using the qMethyl kit (Zymo Research, Irvine, CA, USA) were previously designed and optimized (Bissegger and Langlois, 2016) . The fragments being analyzed for DNA methylation changes were chosen in promoter regions rich in CpG. DNA isolated at different stages of development (NF 2, 13, 21, 25, 29, 34, 41, and 46 ) from three individual samples was analyzed using the qMethyl kit. The DNA methylation percentage was calculated using the C t difference between a reference (no enzymes) and a test (including methylation sensitive restriction enzymes) reaction sample. Each experiment included a methylated and non-methylated DNA standard as a control to ensure the qPCR reaction was working properly.
Probe synthesis for in situ hybridization
Primers were designed using Pubmed for the four srd5 (srd5α1, srd5α2, srd5α3, and srd5β), and eukaryotic elongation factor 1α1 (eef1α1) as a positive control. PCR was used to confirm the correct targeting of the primers using cDNA obtained from S. tropicalis at NF 46. Optimized conditions for PCR can be found in Table 1 . Each gene was then ligated into the pGEM vector (Promega, Madison, WI, USA) and cloned into JM109 competent Escherichia coli (Promega, Madison, WI, USA). Plasmid was extracted using a plasmid mini kit (VWR, Mississauga, ON, Canada) and linearized using the NdeI restriction enzyme (Fisher Scientific, Toronto, ON, Canada). In vitro transcription of each gene was performed using the T7 RNA Polymerase (Roche Applied Science, Laval, QC, Canada) to receive antisense probes labeled with digoxigenin to be used in in situ hybridization.
Whole mount in situ hybridization
The in situ hybridization protocol was adapted from Sive et al. (2000) . Briefly, the embryos were rehydrated, treated with 10 μg/mL proteinase K (embryos after stage NF 32) or treated with 10 μg/mL proteinase K, 2 mg/mL collagenase A, and 20 units/mL hyaluronidase (embryos before stage NF 32), fixed in 4% paraformaldehyde, and hybridized with the desired probe (eef1α1, srd5α1, srd5α2, srd5α3, or srd5β). To account for non-specific binding, each developmental stage and/or treatment was also run through the same experimental procedure without adding any probe (data not shown). In addition, the anti-digoxigenin antibody was pre-adsorbed by incubation overnight with embryos not used for the experiment. Furthermore, in place of sense probes for each srd5 probe, we used the inhibitor experiment with FIN, which successfully inhibited/decreased the expression of all srd5. This control acted as a validation control for no non-specific binding due to the successful decreasing of the mRNA levels of all srd5. Therefore, our suite of controls ensures that the designed probes are specific to the targeted genes and do not result in non-specific signals resulting from the probes binding to other mRNA present in the tissue. After extensive washing of the embryos, the preadsorbed antidigoxigenin Fab fragments coupled to alkaline phosphatase antibody (Roche Applied Science, Laval, QC, Canada) was added at a 1: 2000 dilution overnight at 4°C. The staining with nitro blue tetrazolium (NBT, Sigma, Oakville, ON, Canada)/5-bromo-4-chloro-3′-indolyphosphate p-Toluidine (BCIP, Sigma, Oakville, ON, Canada) was then carried out for 6 h for all srd5 probes, and 45 min for the eef1α1 probe. The embryos were cleared in a mix of 2:1 benzyl benzoate/benzyl alcohol and then stored in methanol in the dark at 4°C. Embryos were rehydrated and mounted in glycerol before taking pictures using a Nikon SMZ-10 stereomicroscope.
Quantification of the mRNA level after whole mount in situ hybridization
To visually quantify the amount of mRNA expression after the exposure to FIN, CA, and UA in exposed and control embryos (n = 5) a scoring system to compare staining intensity (0 = no stain, 1 = light stain, 2 = medium stain, and 3 = strong stain) was established and compartmentalized in head, stomach, and tail regions as shown in Fig. 1 . The examiner that assessed the staining score was blind to the treatment group to avoid experimenter bias. The staining score of head, stomach, and tail regions of each embryo was added up for an overall staining score for each treatment. One-way analysis of variance (ANOVA) was used to analyze any significant changes in mRNA expression. p-value b 0.05 was accounted for as significant.
Results
Enzymatic inhibition
In order to confirm that srd5 transcripts are being converted into active enzymes, specific enzymatic inhibitors for Srd5α1, Srd5α2, Srd5α3, and Srd5β (e.g., FIN, CA, or UA) were tested during early development. The exposure lasted from NF 13 until the embryos reached stage NF 34. This stage was selected as tissue differentiation is clearly apparent and clear staining was achieved in control embryos when using whole mount in situ hybridization (Fig. 2) . Treatment with FIN significantly decreased the mRNA level of all srd5 (srd5α1: p = 0.0159; srd5α2: p = 0.0004; srd5α3: p b 0.0001; srd5β: p = 0.0001) as evaluated by a scoring system visually established (Fig. 3 ). The expression of srd5α2 was not detectable anymore after FIN treatment. The mRNA level of srd5α1 decreased in particular in the head region. The expression of srd5α1 in the stomach region was not decreased by FIN. In contrast, staining attributed to srd5α3 and srd5β mRNA expression decreased in all areas but not completely. Embryos exposed to UA did not show any decrease in the mRNA level of srd5. Embryos exposed to 100 μM CA were shown to result in a significant srd5β reduction (p ≤ 0.0001) across the body whereas all other enzymes did not change in expression abundance.
Specific DNA methylation in the promoter region of srd5α during early development
Specific DNA methylation analysis in the promoter region of the three srd5α isoforms provided novel insight into the regulation mechanism of the gene expression at various stages of early development. The results suggested specific DNA methylation pattern for the genes encoding the three different srd5α isoforms. Specifically, srd5α1 was the isoform with the least amount of DNA methylation in the promoter region when comparing to the other two isoforms (Fig. 4A) . A significant increase in DNA methylation occurred between stages NF 2 and NF 13 (p = 0.002). The DNA methylation profile of srd5α1 did not change significantly in the following stages until the beginning of feeding at NF 46. The isoform found mostly in reproductive tissues, srd5α2, was found to be highly methylated at all stages of development and did not change significantly throughout embryogenesis (Fig. 4B ). The Fig. 2 . Localization of 5α-reductase type 1, 2, 3 (srd5α1, srd5α2, srd5α3) and 5β-reductase (srd5β) mRNA l localized by in situ hybridization at Nieuwkoop and Faber stage 34 with and without inhibition to 100 μM finasteride (FIN), 100 μM ursodeoxycholic acid (UA), or 100 μM chenodeoxycholic acid (CA). Fig. 3 . Relative gene expression observed by whole mount in situ hybridization of 5α-reductase type 1, 2, 3 (srd5α1, srd5α2, srd5α3) and 5β-reductase (srd5β) expressed as a relative staining score of each embryo (n = 5). Nieuwkoop and Faber stage 34 embryos were exposed to finasteride (FIN), ursodeoxycholic acid (UA), or chenodeoxycholic acid (CA). Significant differences are marked with * (p b 0.05) and analyzed by ANOVA.
DNA methylation state of srd5α3 is highly methylated at most stages but changed during the development. The methylation pattern of srd5α3 significantly increased to around 90% at stage NF 13 (p = 0.005) from a very low methylated state at NF 2 (Fig. 4C) . At stage NF 34 the DNA methylation significantly decreased (p = 0.0335) and is in line with increased mRNA expression detected by in situ hybridization.
Developmental expression of srd5 localized using whole mount in situ hybridization
In order to localize the expression pattern of srd5α1, srd5α2, srd5α3, and srd5β mRNA, whole-mount in situ hybridization during blastula (Fig. 5) , neurula (Fig. 5) , tailbud (Fig. 6) , and tadpole development until the start of feeding at stage 46 (Fig. 6 ) was performed by visually observing the intensity of the staining. Although Srd5α1, Srd5α2, Srd5α3 share similar functions, the mRNA sequence similarity between all three isoforms is between 50 and 60%, whereas the Srd5β shares approximately 50% of sequence similarity with the Srd5α isoforms ( Table  2) . Specific mRNA sequences were targeted when designing probes to eliminate cross reactivity between probes.
Expression pattern of srd5α1
Early on, in blastula stage NF 7, srd5α1 transcript is present in the vegetal yolk mass. During neurulation (NF 13 to NF 21), it was observed that the distribution of srd5α1 transcript gradually became more visually distinguishable between tissues: whereas at NF 13 the expression profile is not clearly visible yet, the expression along the neural plate becomes more pronounced at NF 17. The expression of srd5α1 along the neural tube and the notochord is visible at NF 21, which marks the start of organogenesis. At the early tailbud stage (NF 25) expression is localized to the head for srd5α1. Both the spinal cord and the brain showed a slight staining. During the late tailbud stage NF 31, the expression becomes clearly distinct and is visually observable in the spinal cord and brain. In addition, the srd5α1 transcript was also observed in the otic vesicle as well as in the pharyngeal pouch. Furthermore, expression was also visible in the heart, pronephric kidney, stomach, and liver rudiment suggesting a vital role of steroid production in these organs. As the development progresses to NF 34, the expression of srd5α1 is similar to NF 31 regarding to localization of the expression, but decreases in the amount. In terms of NF 41, the expression is localized to the heart, liver, intestine, stomach, otic vesicle, pharyngeal pouch, brain, hindgut, hepatic diverticulum and yolky endoderm. NF 46 marks an early tadpole stage and the start of feeding. High srd5α1 expression is observed in the brain and can be localized to the telencephalon and midbrain. Other areas with lower srd5a1 expression are located to the gill arches, liver, stomach, and intestine.
Expression pattern of srd5α2
srd5α2 transcript is present early on in blastula stage NF 7. At the start of neurulation at NF 13, the expression of srd5α2 is observable along the neural plate. At the end of neurulation (NF 17) the expression decreases below the detection limit. Organogenesis starts at stage NF 21 and expression is marginally visible on the dorsal head region at that stage, but decreases below detection limit again at the early tailbud stage NF 25. The late tailbud stage NF 31 shows increased and localized expression of srd5α2 in spinal cord, stomach, and pharyngeal pouch. As the development progresses to NF 34, expression is also starting to become noticeable in the otic vesicle and brain. Expression of srd5α2 is observed in the otic vesicle, brain, liver, pharyngeal pouch, and heart once reaching NF41. At the early tadpole stage NF46, srd5α2 expression continues to increase and is observed in stomach, intestine, and cloaca.
Expression pattern of srd5α3
The expression of srd5α3 follows a similar pattern as srd5α1. srd5α3 is present at the earliest investigated stage NF 7. At the end of neurulation at NF 17 the expression along the neural tube becomes apparent and staining is clearly visible at the start of organogenesis (NF 21) in different organ systems. Apparent expression is observed in the archencephalon, which later develops into the midbrain and forebrain. NF 25, an early tailbud stage, the expression of srd5α3 is observed in the heart anlage, visceral pouches, and the brain. Expression of srd5α3 becomes more distinct at the late tailbud stage 31 and is present in the otic vesicle, brain, pharyngeal pouches, and spinal cord. Later on, at stage 34, expression is also observed in the heart and liver. Srd5α3 expression decreases in NF 41 larvae but is still detectable in the brain, otic vesicle, and the pharyngeal pouches. In NF 46, the expression level increases and is present in liver, stomach, intestine, gills, and heart.
Expression pattern of srd5β
Expression of srd5β largely follows a similar trend compared to srd5α1 and srd5α3, with the exception that the observed expression level of srd5β increases at the beginning of organogenesis at NF 21. High expression level is visible along the neural tube as well as in the archencephalon. The early tailbud stage NF 25 does not show any expression along the spinal cord but shows expression in the heart anlage, visceral pouch, ear vesicle, and the brain. The expression level of srd5β experiences a dramatic increase in the late tailbud stage NF 31. A high transcript level of srd5β is observed in the spinal cord, pronephric kidney, otic vesicle, brain, pharyngeal pouches, heart, and the liver. The expression of srd5β continues to be present in all these organs until late tailbud stage NF 41. The early tadpole stage NF 46 shows a more distinctive expression pattern in liver, intestine, stomach, kidneys, gills, and midbrain.
Discussion
Previous in silico analysis suggested that the srd5 genes contain androgen responding elements, indicating the expression of these enzymes is subject to the regulation from androgens (Flood et al., 2013) . Moreover, it was previously revealed that exposure to the Srd5 inhibitor FIN led to significantly low levels of srd5α2 and srd5β mRNA in S. tropicalis tadpoles (Langlois et al., 2010b) . As such, we validated that the srd5 transcripts observed are being converted into active proteins (enzymes), as their enzymatic inhibition was successful. However, protein activity was not measured in this particular experiment, but previous in vitro studies have shown successful inhibition of both SRD5α and SRD5β by FIN in human tissues (Drury et al., 2009; Yamana et al., 2010) . Nevertheless, the in situ hybridization data showed that FIN reduced the mRNA level of all srd5 in S. tropicalis at the developmental stage NF 34. It is worth noting that the type 2 isoform exhibited the strongest inhibition, consistent with the previous findings where FIN has demonstrated more inhibitory effect on the expression of Srd5α2 than Srd5α1 (Tian et al., 1994) . Furthermore, similar to our finding, recent data demonstrated that FIN inhibited srd5α3 at a similar potency as srd5α2 in transfected HEK-293 cells (Yamana et al., 2010) . Originally, FIN was developed as a human drug to specifically target SRD5α2 (reviewed in Chen and Penning, 2014) . Inhibition exposure to Srd5 in amphibians previously showed impaired sexual functions, including decreased spermatogenesis, a female biased sex ratio, accelerated ovarian differentiation, and intersex animals (Petrini and Zaccanti, 1998; Urbatzka et al., 2009; Langlois et al., 2011) . In depth analysis of adverse effects of Srd5α inhibition in mammals provided evidence that unfavorable outcomes are not limited to sexual functions (Traish et al., 2015) . For example, an increase in insulin resistance, an increased risk of cardiac failure, an increased rate of osteoporosis, and changes in neurobehavioral functions were observed (Traish et al., 2015) . Thus, a dysfunction of Srd5α can result in a broad range of adverse effects and shows evidence that Srd5α are enzymes producing steroid metabolites that have many crucial roles in an organism. In our study, the localization of srd5α in several organ systems throughout development in S. tropicalis points to the fact that these enzymes are crucial in embryogenesis for proper development as inhibition does occur by the same mechanism as in mammals. In addition, FIN also decreased the mRNA level of srd5β, agreeing with previous reports (Drury et al., 2009) . In order to find a specific inhibitor for Srd5β, we exposed fertilized frog embryos to CA and UA. CA and UA are bile acids that are suggested to provide feedback inhibition for SRD5β in human liver (Chen et al., 2011) . Here, we discovered that CA, but not UA decreased mRNA levels of srd5β, but not srd5α in S. tropicalis. This finding suggests that a similar inhibition feedback mechanism compared to human liver is present in frogs during early development for CA. A dysfunction of Srd5β has been linked to hepatic failures in infants (Lemonde et al., 2003) . The presence of srd5β in tissues other than liver suggests adverse effects if Srd5β activity is lower than normal. With biological functions, including neurosteroid synthesis, initiation of steroid hormone clearance, erythropoiesis, and vasorelaxation, it would be expected that dysregulation of Srd5β results in adverse effects other than hepatic failures (Langlois Fig. 6 . Gene expression of 5-alpha reductase type 1, 2, 3 (srd5α1, srd5α2, srd5α3) and 5-beta reductase (srd5β) during S. tropicalis early development in early and late tailbud Nieuwkoop and Faber (NF) stages 25 through 41 and early tadpole stage NF 46 localized by whole mount in situ hybridization. Legend: b: brain; c: cloaca; ev: ear vesicle; fb: forebrain; g: gills; ha: heart anlage; h: heart; hg: hind gut; i: intestine; k: kidney; l: liver; mb: midbrain; ov: otic vesicle; pk: pronephric kidney; pp.: pharyngeal pouch; s: stomach; sc: spinal cord; vp: visceral pouch; y: yolky endoderm. , 2010a; Chen and Penning, 2014) . Thus, a dysregulation of Srd5 potentially leads to detrimental developmental defects. According to our results, the regulation mechanism of srd5α and srd5β in the frog embryo are self-regulated when exposed to specific Srd5 inhibitors, with decreasing mRNA levels after exposure. These data correspond to a previous study that exposed frog embryos to FIN (Langlois et al., 2010b) . In contrast, in vivo FIN exposure to frog tadpoles until after metamorphosis showed tissue-dependent regulation mechanisms of Srd5. The frog brain was not affected by Srd5 inhibition, while the liver experienced a decrease in srd5α2 mRNA and testicular tissue resulted in an increase in srd5α2 mRNA (Urbatzka et al., 2009; Duarte-Guterman et al., 2009; Langlois et al., 2011) . These findings suggest that the regulation of Srd5 is tissue-specific and may be due to a differing response on gonadotropin hormone feedback in different tissues. Currently, little is known regarding the regulation of Srd5 enzymes during embryogenesis. In particular, no previous research has shown that the transcriptional regulation of the three srd5α isozymes is different. The presence of isoform-specific expression pattern of srd5α in various tissues proposes a distinctive regulatory mechanism for the three srd5α isozymes. We explored the possibility of DNA methylation being part of the transcriptional control for the srd5α enzymes. DNA methylation is a key regulator for gene expression and is tightly regulated during normal embryonic development (Chen and Riggs, 2005; Meehan et al., 2005) . In Xenopus embryos, DNA methylation is typically associated to gene silencing prior to transcriptional initiation (Stancheva and Meehan, 2000) . After onset of acquiring the ability of gene transcription at the mid-blastula transition stage, global DNA methylation level sees decreases, possibly leading to changes in DNA methylation of individual gene promoters (Stancheva et al., 2002) . In S. tropicalis embryos, the three srd5α isoforms exhibited different specific DNA methylation profiles. First, the lowest DNA methylation level observed in srd5α1 coincides with the highest expression of this isoform throughout development, especially in the later stages. It should be noted that as opposed to the localized mRNA observed by in situ hybridization, the DNA methylation pattern was analyzed in the whole body and is compared best to mRNA data obtained by quantitative RT-PCR from whole body animal. Langlois et al. (2010b) quantified mRNA of the three srd5α isoforms by quantitative RT-PCR. In this study, the general trend of DNA methylation pattern of srd5α1 coincides with the abundance of mRNA level in whole larvae suggesting that DNA methylation is involved in regulating the expression level of srd5α1 (Fig. 7A) . Interestingly, srd5α2 (the isoform mostly found in reproductive tissues of adults) was found to be highly methylated at all stages of development. In contrast, mRNA of srd5α2 detected by in situ hybridization and quantitative RT-PCR (Langlois et al., 2010b) revealed changing mRNA levels (Fig. 7B) . However, due to the lower expression level of srd5α2 compared to srd5α1 and srd5α3, a change in DNA methylation may be more difficult to observe. Thus, DNA methylation control of srd5α2 is not ruled out, but needs further investigation. In contrary, the DNA methylation pattern of srd5α3 changed throughout development and is consistent with the results from in situ hybridization, as well as quantitative RT-PCR results (Langlois et al., 2010b, Fig. 7C ). Taken together, it appears that DNA methylation is involved in regulating srd5α1 and srd5α3 expression in S. tropicalis during early development. Although we observed a correlation between the srd5α1 and srd5α3 mRNA levels and their related DNA methylation percentage, which supports that the analyzed short promoter fragments are involved in the regulation of the expression of these genes, future experiments should investigate DNA methylation patterns on the complete promoter region of srd5α1, srd5α2, and srd5α3 in amphibians. Nevertheless, our findings expand on the previous report that the expression of both, srd5α1 and srd5α2, are regulated by DNA methylation in rat testis and human tissues (Reyes et al., 1997; Rodrıǵuez-Dorantes et al., 2002; Moribe et al., 2008; Tsunedomi et al., 2010) . DNA methylation imprinting is inherited. Thus, a transgenerational effect in the regulation of srd5α is expected via maternal transfer. A modified DNA methylation pattern may lead to changes in gene regulation and subsequently lead to developmental defects. Studies have previously shown that an altered DNA methylation pattern in the germ line induced by endocrine disrupters (e.g., vinclozolin and methoxychlor) is associated to decreased spermatogenesis in rats and promotes transgenerational diseases (Anway et al., 2005) . Thus, the study of transgenerational effects on the regulation of Srd5 is important to understand possible implications by interference with environmental compounds.
The developmental profile data show that maternally transferred mRNA was present for all srd5 in the stages prior to NF 8. This correlates with another study, which quantified the expression of srd5 in S. tropicalis (Langlois et al., 2010b) . Maternal mRNA has been previously detected in mammals (Telford et al., 1990) , amphibians (Kloc et al., 2001; King et al., 2005; Heasman, 2006a) , and fish (Aegerter et al., 2004) . Maternally transferred mRNA is essential before the onset of transcription for embryonic patterning, controlling cell division, and basic biosynthetic processes (Heasman, 2006b; Tadros and Lipshitz, 2009; Lee et al., 2014) . The presence of srd5 early on suggests that these enzymes are involved in synthesizing steroids during embryogenesis before the onset of transcription. For Xenopus spp., the ability to transcribe genes is developed during mid-blastula transition (NF 8; Fig. 7 . Correlation comparison between mRNA levels and specific DNA methylation % of A) srd5α1, B) srd5α2, and C) srd5α3. mRNA level data (measured by RT-qPCR) was extracted from a previous experiment published by Langlois et al. (2010b) . Note that the Y-axis increment varies among panels. Newport and Kirschner, 1982) , which correlates to this present study. Once passing the onset of the start of gene transcription, specific expression of srd5α1, srd5α2, srd5α3, and srd5β is present and changes in concentration and location, indicating the ability of transcribing genes. srd5 transcripts were present throughout early development in organs associated with the central nervous system (CNS), digestive tract, sensory-, cardiac-, respiratory-, and detoxifying systems in the anuran S. tropicalis (Table 3) .
srd5 mRNA transcripts were observed early on in tissues related to the CNS suggesting that these enzymes might play a role in the development of the CNS in amphibians. Presence of srd5α1 in the notochord suggests a potential role for 5α-reduced steroids in this tissue. The notochord is involved in the signalling and coordination of development (Malikova et al., 2007) . Moreover, throughout early frog development we found that, depending on the stage, transcripts of srd5 are also present at different transcript levels in the neural plate, neural tube, and spinal cord. Other studies also observed Srd5α in human, rat, and frog spinal cord (Jurman et al., 1982; Poletti et al., 1998; Pozzi et al., 2003) . In addition, transcripts of all srd5 isoforms were detected in the developing frog brain, suggesting that 5α-reduced steroids are necessary during the brain development. Previous studies have shown that the development of the brain during adolescence responds to sex steroids and show sex specific differences (Koolschijn et al., 2014) . Moreover, in the bullfrog, 5α-DHT is responsible for maintaining the sexual dimorphism of the pretrigeminal nucleus (Boyd et al., 1992) . Other studies revealed that Srd5 isoforms were observed in the endoplasmic reticulum of neurons and play an important role in the development of sexually-dimorphic structures in the brain (Behan et al., 2003) . In addition, isoformspecific distribution is present in the brain during development and adulthood for Srd5 enzymes. In particular, Srd5α2 was localized only in specific tissues and time periods. In both rat and guinea pig brains, the mRNA level of srd5α2 was significantly higher before birth than after, also with region-specific distribution patterns (Poletti and Martini, 1999; Kelleher et al., 2013) . Moreover, the level of srd5α2 mRNA was shown to gradually decrease throughout metamorphosis in brains of S. tropicalis and Xenopus laevis, with the lowest mRNA level in NF 66 frog brains (Urbatzka et al., 2007; Duarte-Guterman and Trudeau, 2010) . Similarly, our data revealed decreasing expression levels of srd5α2 in brain throughout development, suggesting the expression pattern of srd5α2 in S. tropicalis being consistent to other species. Srd5α1, however, was detected in high quantities in the frog brain, agreeing with the previous studies in rat, human, and frog that have shown that srd5α1 is more abundant in brain than srd5α2 (Poletti et al., 1997 (Poletti et al., , 1998 Urbatzka et al., 2007) . Similar to srd5α1, srd5β was also observed at high expression levels in the frog brain throughout development. Although Srd5β is known for its major function in bile biosynthesis in the liver (Chen and Penning, 2014) , it has also been found in brain. Studies have observed Srd5β in avian brain and suggested an important role of Srd5β in inactivating T to 5β-DHT to protect the brain from androgenic action (Balthazart et al., 1986; Tobet and Handa, 2009) . Furthermore, our previous study also demonstrated that brain exposed to T resulted in an increase of srd5β mRNA in adult frogs (Bissegger and Langlois, 2016) . Thus, it seems that the presence of srd5β throughout early development in the frog may be functionally consistent with the observations from previous studies. However, future functional analysis using knock-out models and subsequent malformation analysis to observe developmental defects resulting from Srd5 deficiency could be useful to establish exact functions of Srd5.
Androgens are also known to be present in the heart. For example, T and 5α-DHT stimulate the proliferation of cardiac myocytes (Kienitz and Quinkler, 2008) . Our results revealed that in frogs the transcripts of srd5β, srd5α1, and srd5α3 were all present in the heart anlage as well as in the fully developed heart. Srd5 has also been detected in the heart tissue of other species (Langlois et al., 2010a; Chávez et al., 2014) . However, in the frog, srd5α3 was the only gene that was expressed in heart tissue at the most developed stage tested (i.e. NF 46), suggesting a predominant presence of this particular isoform in the heart later in development. Interestingly, however, srd5α2 expression was not observed in the tissues related to the cardiac system, which corresponds to previous studies suggesting that Srd5α2 is mostly present in reproductive tissues (Langlois et al., 2010a) . Srd5α3 is the most recently discovered isoform in the Srd5α family and little is known about its exact functions. While some studies propose that human and hamster Srd5α3 have no catalytic capability to convert T and other 3-keto-4-ene steroids in vitro (Chávez et al., 2014) , other research shows the ability of Srd5α3 to reduce T and other 3-keto-4-ene steroids in vitro (Titus et al., 2014) .
In addition to functions related to the heart, srd5α3 was also detected in the respiratory system along with the other srd5 enzymes. Specifically, srd5 enzymes are expressed in the pharyngeal pouch during early developmental stages, which would eventually develop into gill arches where the transcripts for all srd5 are also observed in the corresponding stages. This observation indicates that in amphibians, Srd5 enzymes and possibly androgens might be part of the respiratory system development process. In mice and humans, srd5α1 and, although to a lower extent, srd5α2 are present in the developing lung, whose development has also been demonstrated to be heavily influenced by administration of synthesized androgens (Aumüller et al., 1996; Seaborn et al., 2010; Mikkonen et al., 2010) . In particular, androgens stimulate airway branching morphology and cell proliferation (Volpe et al., 2013) . Moreover, T reportedly attributes to assisting the control of breathing in humans, as well as modulating cellular respiration and intracellular oxygen level in cancer cell lines (Saaresranta and Polo, 2002; Behan et al., 2003; Prior et al., 2014) . Thus, it is not surprising that Srd5 enzymes might also hold significant roles in the development of the respiratory system in amphibians. n/a n/a n/a n/a Cardiac system n/a n/a n/a n/a Respiration n/a n/a n/a n/a Detoxifying system n/a n/a n/a n/a Digestive tract n/a n/a n/a n/a 25 CNS − − + + Sensory system − − − + Cardiac system + − + + Respiration + − + + Detoxifying system n/a n/a n/a n/a Digestive tract n/a n/a n/a n/ In addition, expression of srd5 enzymes was detected in detoxification and digestive tissues. For example, srd5 was expressed in liver, starting at stage NF 31, which coincides with the start of liver formation. The liver is responsible for detoxification and metabolizing hormones. A high level of srd5α1 is found in rat hepatocytes, for inactivating androgens (El-Awady et al., 2004) . Similarly, srd5α1 is expressed continuously, spanning from stage NF 31 to NF 46. In contrast, srd5α2 mRNA was only detected at NF 41, indicating an isoform-specific expression pattern. srd5β transcript is also abundant in liver, which is expected as the enzyme features pivotal function in bile acid synthesis (Chen and Penning, 2014) .
Conclusion
With the help of in situ hybridization, the current study demonstrated for the first time that steroid metabolites synthesized by Srd5α and Srd5β may have crucial roles in multiple tissues during early amphibian development. Moreover, our results revealed that specific DNA methylation may serve as a part of the regulation of the expression for srd5α1 and srd5α3. In addition, inhibition studies showed that gene regulation of srd5 in early frog development is based on a positive feedback loop mechanism. Taken together, our study provides novel insight on srd5 transcript tissue localization and potential mechanisms behind srd5 expression regulation during frog early development, and provides evidence that Srd5 are functional during the critical early developmental period.
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